Hyung Don Ryoo: A healthy career in cellular death by Williams, Ruth
People & Ideas
JCB • VOLUME 185 • NUMBER 5 • 2009 758
I
n the body, some cells must sacrifi  ce 
themselves for the greater good. Cell 
suicide (apoptosis) is essential for 
sculpting the body during development 
and for eliminating damaged or potentially 
dangerous cells that might cause disease.
At his laboratory at New York Uni-
versity, Hyung Don Ryoo uses the fl  y to 
study the molecular pathways that control 
apoptosis. His love for this model organism 
started during his graduate studies on Hox 
transcription factor regulation during devel-
opment (1, 2). His choice to study apoptosis, 
however, was more of a carefully thought-
out career plan. Indeed, in a recent interview 
with Ryoo, it was clear that his motivation 
is to be in the best position for making new 
discoveries, regardless of the fi  eld.
Ryoo’s apoptosis studies started dur-
ing his postdoc with Hermann Steller at 
the Rockefeller University (3, 4), and con-
tinue in his own laboratory (5). Though, 
true to form, Ryoo has recently moved into 
another fi  eld—ER stress (6, 7). What’s his 
ultimate career aim? To start a whole new 
fi  eld of his own, of course.
KNOWING WHAT NOT 
TO BE
Where did you grow up?
In Seoul, Korea. I spent three 
years in New York when I 
was a child, because my fa-
ther had a job here, but spent 
most of my youth in Korea.I 
went to college there, and 
then did military service.
Tell me about your 
military service.
It was for two and a half years 
after college, so I must have been 22 to 24. 
I was assigned to a military hospital. It was 
mainly menial work, getting military 
medical supplies. We also did basic mili-
tary training.
Korea was a very militaristic soci-
ety—we had former generals ruling the 
country until the mid-80s. As a child, one 
of my favorite movies was Platoon by 
Oliver Stone. But these boyhood fascina-
tions toward the military disappeared dur-
ing my military service.
Why?
In movies you see John Wayne-like fi  g-
ures, Rambo-like fi  gures—one hero against 
an entire enemy army. But an individual is 
weak, and in the military, oftentimes out of 
fatigue, you get to hate your colleagues 
more than perhaps the other side.
No military career for you then! Did you 
consider anything other than science?
I was always pretty sure that I wanted to 
pursue science. I thought about physics, 
but my mother was strongly opposed 
because of a cousin of mine. He broke the 
all-time grade point average at Caltech in 
the 70s, and then went on to do his gradu-
ate studies at Harvard, studying theoretical 
particle physics. But after he had obtained 
his PhD and did a few years of postdoc, he 
left science because he couldn’t get a job. 
So, I studied biochemistry instead.
GETTING GOOD 
TRAINING
You moved to Columbia 
University in New York 
for your graduate studies. 
Why there?
Among the places that I was 
accepted, Columbia was 
probably the most reputable. 
There could’ve also been 
some emotional value at-
tached to Columbia because 
of my childhood years in 
New York. I remembered 
visiting the beautiful Columbia campus 
with my cousin, who was interviewing 
there for his own graduate studies.
You joined Richard Mann’s Laboratory?
Yes. Richard’s laboratory was my second 
rotation. We were supposed to do three rota-
tions, but I asked for special permission. 
I went to my graduate adviser, said, “I’m 
set, I know that this is the lab that I want 
to work in,” and I stayed there.
Back then Richard was a molecu-
lar biologist making a transition into 
developmental biology. He started his 
fl  y laboratory just a few years before I 
arrived there.
Because of his mixed background, 
Richard’s seminars were really fascinating. 
Lots of biochemistry, molecular biology, 
three-dimensional crystal structures, and 
then ultimately in vivo tests using fl  y 
genetics. When I saw that, I immediately 
realized that was the kind of training I 
wanted—well-rounded and incorporating 
lots of different disciplines.
What did you study?
Right before I joined the laboratory, Rich-
ard had shown that Hox proteins have 
cofactors—called Exd—and that the two 
bind together on DNA.
There was a big debate in the fi  eld 
as to whether these were specifi  city-
conferring cofactors. And my thesis work 
determined that, yes, they are.
CRAFTING A CAREER PATH
How did you pick your postdoc?
I really got to appreciate the power of the 
fl  y as a model organism. But the Drosophila 
community was poorly represented out-
side the fi  eld of developmental biology. 
Ryoo engages the power of the fly to study apoptosis during 
development and disease.
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I wanted to fi  nd some new directions that 
would allow me to branch out. In that re-
gard, I thought apoptosis was probably a 
good place to start, because it’s associated 
with a wide spectrum of processes—devel-
opmental apoptosis sculpts the body shape; 
too much cell death can lead to diseases 
like neurodegenerative disorders; too little 
cell death is associated with cancer.
As a young scientist trying to make 
a career, choosing your postdoc plays a big 
role in determining your future research. 
Finding the right postdoctoral 
laboratory is really challenging 
because the laboratory should 
be reputable, you have to get 
along with the group leader, 
the topic should be something 
interesting, but on top of that 
you have to ask, can I see my-
self branching out in an inde-
pendent direction afterwards?
I made the conclusion 
that Hermann Stellers’ labo-
ratory at Rockefeller would 
provide all of that.
So you chose apoptosis as a career 
move as opposed to being passionately 
interested in the subject?
Well, yes. I do think a lot about whether 
there will be new opportunities of discov-
ery before taking a new direction. There 
are scientists who start their seminars by 
saying they saw gastrulation when they 
were in high school, and they fell in love 
instantaneously. I didn’t have any such 
experiences as a young child. Also, I feel 
that science is a rapidly changing discipline, 
and if you’re at the right place, in the right 
position, you can run into the most unex-
pected discoveries. I see that as the source 
of my excitement. The emphasis would be 
on trying to fi  nd something novel, rather 
than something that I had fallen in love 
with many years ago.
When did you decide on your latest 
direction?
I started thinking about which direction to 
branch out into after I published my fi  rst 
paper on apoptosis from Hermann’s labo-
ratory, in 2002. I realized that many other 
people were doing similar experiments.
The unfolded protein response fi  eld 
was growing at the time and really reminded 
me of the apoptosis fi  eld in the 90s. Apop-
tosis lectures used to start out by saying, 
“If we understand apoptosis well, then we 
can understand development and cancer 
and neurodegenerative disease, viral infec-
tion,  and everything,” and you wonder, 
“What is apoptosis not related to?” In the 
early 2000s, the unfolded protein response 
lectures started a similar way. “It’s related 
to virtually every known important prob-
lem in the world, and if we understand that 
well, then we’ll bring about world peace.”
Whether that’s true 
or not, I thought that 
bringing in a new model 
organism, like fl  ies, 
would generate lots of 
exciting discoveries—
the pioneering work had 
been done in yeast and 
mammalian culture cells. 
Particularly, I thought 
the fl   ies would be an 
excellent model to study 
the connection between 
ER stress and apoptosis. 
So in 2002 I started devel-
oping  some tools to study the unfolded 
protein response using fruit fl  ies.
Another well-planned career move.
If I’m doing the same thing that everyone 
else is doing, then I would be dispensable.
In science there’s a lot of that, espe-
cially in crowded and competitive fi  elds. 
In fact, if you left, it’s likely everyone else 
would be really happy. So, the goal has to 
be to come up with questions that other 
people are not asking, or approaches that 
other people are not taking. That’s how to 
make important discoveries that have an 
impact—something that would end up 
being useful to others. That’s the concep-
tual goal that I’ve always had.
At what point did you know you wanted 
to be a group leader?
That was always the aim, since I was an 
undergrad. If you’re a group leader, then 
you can actually direct your own research, 
come up with creative ideas, and take the 
initiative. That’s what I wanted.
Is it as good as you thought it would be?
Yes. It’s really exciting. I feel like the kind 
of research that’s going on in my labora-
tory is the best I’ve ever done. I guess part 
of it is the freedom; I can do whatever I 
want. The second thing is, I have people 
in my laboratory, so I don’t have to spend 
all my time doing mini-preps. I can spend 
more time discussing ideas.
Now you’ve made it to group leader, 
what’s next?
I’m still in a learning process here, but of 
course the most desirable scenario is that 
I start a new fi  eld all by myself and make 
it very important down the road. But until 
that happens, the next best scenario is to 
work in an important fi   eld and fi  nd  a 
unique approach to studying it.
It’s also important to me that my 
work has some meaning in this world. 
Since none of my family members, includ-
ing my wife, are scientists, I should be able 
to tell them that whatever we’re working 
on is relevant to the general public.
If you’re surrounded only by scientists, 
then I guess you can really excite each other 
by discussing the fact that the 256th amino 
acid is behaving a little differently. My father 
is an elderly banker. Disease, particularly 
age-related, is something he can relate to. 
It’s important to me that I can talk about my 
work with him. Otherwise, we’d be talking 
about the economy all the time.
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Undead cells in the ﬂ  y eye (right). The cells 
initiate but fail to execute apoptosis, and then 
overgrow. This is one of the many apoptosis 
anomalies that Ryoo studies.
“The most 
desirable 
scenario is 
that I start a 
new field all 
by myself and 
make it very 
important down 
the road.”